

Reference: FOI.ICB-2223/029

Subject: Community Dermatology Services

*I can confirm that the ICB **does hold some of the information requested**; please see responses below:*

QUESTION	RESPONSE
1. Does the Integrated Care Board commission Community Dermatology Services? If yes, what was the total number of patients treated by the Community Dermatology Providers in the last 12 months?	Yes, the total number of patients who have completed treatment (completed referral to treatment time pathways) delivered by Sirona care and health Dermatology Service in the last 12 months (August 2021 to July 2022) is 1496.
2. Who are the Community Dermatology Service Providers commissioned by the Integrated Care Board? Can you please provide the number of patients treated by each provider within the last 12 months?	Sirona care and health – 1496 patients have completed treatment (completed referral to treatment time pathways) in the last 12 months.
3. Do the Community Dermatology Service providers treat patients with any of the following drug types? <ul style="list-style-type: none"> • Monoclonal antibody drugs (e.g. Adalimumab, Dupilumab, Secukinumab, Ustekinumab) • JAK inhibitors (e.g. Abrocitinib, Baricitinib) 	No, these are hospital only medicines.
4. Do the Community Dermatology Service providers initiate treatment with any of the following drug types? <ul style="list-style-type: none"> • Monoclonal antibody drugs (e.g. Adalimumab, Dupilumab, Secukinumab, Ustekinumab) 	No, these are hospital only medicines.

<ul style="list-style-type: none">• JAK inhibitors (e.g. Abrocitinib, Baricitinib)	
--	--

The information provided in this response is accurate as of 10 August 2022 and has been approved for release by Lisa Manson, Director of Commissioning for NHS Bristol, North Somerset and South Gloucestershire ICB.